P2X7 receptor isoform B is a key drug resistance mediator for neuroblastoma.

Autor:	Arnaud-Sampaio VF; Biochemistry Department, Institute of Chemistry, University of Sao Paulo, Sao Paulo, SP, Brazil., Bento CA; Biochemistry Department, Institute of Chemistry, University of Sao Paulo, Sao Paulo, SP, Brazil., Glaser T; Biochemistry Department, Institute of Chemistry, University of Sao Paulo, Sao Paulo, SP, Brazil., Adinolfi E; Section of Experimental Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy., Ulrich H; Biochemistry Department, Institute of Chemistry, University of Sao Paulo, Sao Paulo, SP, Brazil., Lameu C; Biochemistry Department, Institute of Chemistry, University of Sao Paulo, Sao Paulo, SP, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 Aug 25; Vol. 12, pp. 966404. Date of Electronic Publication: 2022 Aug 25 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.966404
Abstrakt:	Drug resistance is a major challenge for all oncological treatments that involve the use of cytotoxic agents. Recent therapeutic alternatives cannot circumvent the ability of cancer cells to adapt or alter the natural selection of resistant cells, so the problem persists. In neuroblastoma, recurrence can occur in up to 50% of high-risk patients. Therefore, the identification of novel therapeutic targets capable of modulating survival or death following classical antitumor interventions is crucial to address this problem. In this study, we investigated the role of the P2X7 receptor in chemoresistance. Here, we elucidated the contributions of P2X7 receptor A and B isoforms to neuroblastoma chemoresistance, demonstrating that the B isoform favors resistance through a combination of mechanisms involving drug efflux via MRP-type transporters, resistance to retinoids, retaining cells in a stem-like phenotype, suppression of autophagy, and EMT induction, while the A isoform has opposite and complementary roles. Competing Interests: HU is a scientific adviser of TissueGnostics, Vienna, Austria, and receives consulting fees. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Arnaud-Sampaio, Bento, Glaser, Adinolfi, Ulrich and Lameu.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu